Not found

Seyed Moghimi, PhD

Full Affiliate Member, Research Institute
Houston Methodist


Dr. Moghimi earned his Bachelor degree in Biochemistry with Honors from the University of Manchester (UK), and his Doctorate in Biochemistry/Immunobiology from Charing Cross and Westminster Medical School, Imperial College, London. Following postdoctoral training and a University Fellowship at the School of Pharmaceutical Sciences at Nottingham University (UK), he moved to the University of Brighton as a senior lecturer in Biopharmacy and Molecular Therapy. In 2008, he accepted the chair of Nanomedicine at the University of Copenhagen (Denmark), where he currently heads the Nanomedicine Research Group at the School of Pharmacy, Faculty of Health and Medical Sciences. In 2009, he founded the Centre for Pharmaceutical Nanotechnology and Nanotoxicology (CPNN) at the NanoScience Centre of Copenhagen University through a multi-million dollar award by the Strategic Research Council of Denmark, where he acts in the capacity of centre director. Dr. Moghimi is also the honorary professor of Nanomedicine at the Multidisciplinary Research Center, Shantou University (China) and an elected fellow of the Institute of Nanotechnology in the UK. Since 2009, Dr. Moghimi has secured over US$13 million in competitive research funds in basic and applied nanomedicine research as the principal investigator and is currently a partner in two large-scale competitive European Commission FP-7 programs in translational nanomedicine/drug delivery, addressing Alzheimer’s disease and atherosclerosis with secured budgets of US$ 14.5 million and US$ 11 million, respectively.

Dr. Moghimi serves as the associate editor of Nanomedicine: Nanotechnology, Biology and Medicine (Elsevier) and the Journal of Biomedical Nanotechnology, and sits on the editorial/advisory board of over 15 peer-reviewed international journals, including Advanced Drug Delivery Reviews, Nanomedicine-UK (Future Medicine), and Molecular and Cellular Therapies (BioMed Central). Dr. Moghimi has been a practicing consultant to numerous pharmaceutical, biotechnology, health and food industry companies as well as investment banks, management consultancy firms, and other entrepreneurial enterprises globally for over two decades. He is also a regularly invited assessor and expert evaluator in nanomedicine and pharmaceutical science research centers/research projects for governmental bodies, research councils, and private organizations worldwide (> 50 establishments in 20 countries). As a frequent keynote and guest speaker at many international conferences and organizations, as well as being regular conference chair and organizer, Dr. Moghimi has given over 300 invited speeches and lectures. He has published over 170 peer-reviewed articles in prestigious international journals and book chapters, and is the inventor of many patents.

Description of Research

Dr. Moghimi’s research activities are focused on pharmaceutical nanoscience, nanotechnology in iMedicine, nanotoxicology and fundamental/translational nanomedicine in relation to cancer, neurodegenerative diseases, cardiovascular diseases, and immunological disorders. He has pioneered research in the design and surface engineering of nanoparticles and functional nanosystems for parenteral site-specific targeting/drug delivery and imaging modalities (e.g., splenotropic entities, lymphotropic agents, ‘phagocyte-resistant’ nanoparticles, cancer nanomedicine, cerebral endothelial-specific nanoparticle-fiber networks) as well as the molecular basis of nanomaterial immune toxicity, polymer cytotoxicity, and preventive measures.

Areas Of Expertise

Brain targeting Cancer Complement system Nanomedicine Nanotoxicology
Education & Training

, Charing Cross and Westminster Medical School, Imperial College, University of Long, London
, University Hospital of Nottingham

A structurally diverse library of safe-by-design citrem-phospholipid lamellar and non-lamellar liquid crystalline nano-assemblies
Azmi, IDM, Wibroe, PP, Wu, LP, Kazem, AI, Amenitsch, H, Moghimi, SM & Yaghmur, A 2016, Journal of Controlled Release, vol 239, pp. 1-9. DOI:

Call for papers: Nanoparticle Development and Applications in Cellular and Molecular Therapies
Frederickson, RM, Moghimi, SM, Wagner, E & Yla-Herttuala, S 2016, Molecular Therapy, vol 24, no. 8, pp. 1334-1335. DOI:

Complement propriety and conspiracy in nanomedicine: Perspective and a hypothesis
Moghimi, SM 2016, Nucleic Acid Therapeutics, vol 26, no. 2, pp. 67-72. DOI:

Soluble and immobilized graphene oxide activates complement system differently dependent on surface oxidation state
Wibroe, PP, Petersen, SV, Bovet, N, Laursen, BW & Moghimi, SM 2016, Biomaterials, vol 78, pp. 20-26. DOI:

An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome
Wibroe, PP, Ahmadvand, D, Oghabian, MA, Yaghmur, A & Moghimi, SM 2016, Journal of Controlled Release, vol 221, pp. 1-8. DOI:

Platelet mimicry: The emperor's new clothes?
Moghimi, SM, Hunter, AC & Peer, D 2016, Nanomedicine: Nanotechnology, Biology, and Medicine, vol 12, no. 1, pp. 245-248. DOI:

Cubosomes and hexosomes as versatile platforms for drug delivery
Azmi, IDM, Moghimi, SM & Yaghmur, A 2015, Therapeutic Delivery, vol 6, no. 12, pp. 1347-1364. DOI:

Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake
Inturi, S, Wang, G, Chen, F, Banda, NK, Holers, VM, Wu, L, Moghimi, SM & Simberg, D 2015, ACS Nano, vol 9, no. 11, pp. 10758-10768. DOI:

Citrem modulates internal nanostructure of glyceryl monooleate dispersions and bypasses complement activation: Towards development of safe tunable intravenous lipid nanocarriers
Wibroe, PP, Mat Azmi, ID, Nilsson, C, Yaghmur, A & Moghimi, SM 2015, Nanomedicine: Nanotechnology, Biology, and Medicine, vol 11, no. 8, pp. 1909-1914. DOI:

Meet our editorial board member
Moghimi, SM 2015, Current Pharmaceutical Biotechnology, vol 16, no. 10, pp. 851-852.

Dendrimers in Medicine: Therapeutic Concepts and Pharmaceutical Challenges
Wu, LP, Ficker, M, Christensen, JB, Trohopoulos, PN & Moghimi, SM 2015, Bioconjugate Chemistry, vol 26, no. 7, pp. 1198-1211. DOI:

Differential modulation of cellular bioenergetics by poly(l -lysine)s of different molecular weights
Hall, A, Wu, LP, Parhamifar, L & Moghimi, SM 2015, Biomacromolecules, vol 16, no. 7, pp. 2119-2126. DOI:

Insidious pathogen-mimicking properties of nanoparticles in triggering the lectin pathway of the complement system
Moghimi, SM, Wibroe, PP, Wu, L & Farhangrazi, ZS 2015, European Journal of Nanomedicine, vol 7, no. 3, pp. 263-268. DOI:

Modulatory effect of human plasma on the internal nanostructure and size characteristics of liquid-crystalline nanocarriers
Mat Azmi, ID, Wu, L, Wibroe, PP, Nilsson, C, Østergaard, J, Stürup, S, Gammelgaard, B, Urtti, A, Moghimi, SM & Yaghmur, A 2015, Langmuir, vol 31, no. 18, pp. 5042-5049. DOI:

New platforms for multi-functional ocular lenses: Engineering double-sided functionalized nano-coatings
Mehta, P, Justo, L, Walsh, S, Arshad, MS, Wilson, CG, OSullivan, CK, Moghimi, SM, Vizirianakis, IS, Avgoustakis, K, Fatouros, DG & Ahmad, Z 2015, Journal of Drug Targeting, vol 23, no. 4, pp. 305-310. DOI:

Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid-ß levels in APP/PS1 transgenic mice
Ordóñez-Gutiérrez, L, Re, F, Bereczki, E, Ioja, E, Gregori, M, Andersen, AJ, Antón, M, Moghimi, SM, Pei, JJ, Masserini, M & Wandosell, F 2015, Nanomedicine: Nanotechnology, Biology, and Medicine, vol 11, no. 2, pp. 421-430. DOI:

Polyethylenimine architecture-dependent metabolic imprints and perturbation of cellular redox homeostasis
Hall, A, Parhamifar, L, Lange, MK, Meyle, KD, Sanderhoff, M, Andersen, H, Roursgaard, M, Larsen, AK, Jensen, PB, Christensen, C, Bartek, J & Moghimi, SM 2015, Biochimica et Biophysica Acta - Bioenergetics, vol 1847, no. 3, pp. 328-342. DOI:

Cancer nanomedicine and the complement system activation paradigm: Anaphylaxis and tumour growth
Moghimi, SM 2014, Journal of Controlled Release, vol 190, pp. 556-562. DOI:

Live-cell fluorescent microscopy platforms for real-time monitoring of polyplex-cell interaction: Basic guidelines
Parhamifar, L, Wu, L, Andersen, H & Moghimi, SM 2014, Methods, vol 68, no. 2, pp. 300-307. DOI:

Just so stories: The random acts of anti-cancer nanomedicine performance
Moghimi, SM & Farhangrazi, ZS 2014, Nanomedicine: Nanotechnology, Biology, and Medicine, vol 10, no. 8, pp. 1661-1666. DOI: